Resolution of cerebral vasospasm with trapidil; an animal model

Journal of Clinical Neuroscience

Volumn 9, Issue 4, 2002, Pages 429-432

  Bagdatoglu, Celal ^a   Guleryuz, Adil ^a   Unlu, Agahan ^b   Kanik, Arzu ^a   Berk, Caglar ^c   Ozdemir, Cengiz ^a   Koksel, Turgut ^a   Egemen, Nihat ^b  

^a MERSIN UNIVERSITY   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Basilar artery; Cerebral vasospasm; Rabbit; Trapidil

Indexed keywords

TRAPIDIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASILAR ARTERY; BLEEDING; BRAIN VASOSPASM; CLINICAL PRACTICE; CONTROLLED STUDY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RABBIT;

EID: 0036656180     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1054/jocn.2001.1009     Document Type: Article

References (49)

1. Bell TE, Kongable GL. Innovations in aneurysmal subarachnoid hemorrhage: intracisternal t-PA for the prevention of vasospasm. J Neurosci Nuts 1996; 28(2): 107-113.
2. Megyesi JF, Findlay JM, Vollrath B et al. In vivo angioplasty prevents the development of vasospasm in canine carotid arteries. Stroke 1997; 28: 1216-1224.
3. Miburn JM, Moran CJ, Cross DT et al. Increase in diameters of vasospastic intracranial arteries by intraarterial papaverine administration. J Neurosurgery 1998; 88: 38-42.
4. Eliott JP, Newell DW, Lam DJ et al. Comparison of balloon angioplasty and papaverine infusion for the treatment of vasospasm following aneurysmal subarachnoid hemorrhage. J Neurosurg 1998; 88(2): 277-284.
5. Fandino J, Kaku Y, Schuknecht B et al. Improvement of cerebral oxygenation patterns and metabolic validation of super selective intraarterial infusion of papaverine for the treatment of cerebral vasospasm. J Neurosurg 1998; 89(1): 93-100.
6. Thomas JE, Nemirovsky A, Zelman V, Giannotta SL. Rapid reversal of Endothelin-1-induced cerebral Vasoconstriction by intrathecal administration of nitric oxide donors. Neurosurgery 1997; 40: 1245-1249.
7. Clozel M, Watanable H. BQ-123, a pepditic endothelin ETA receptor antagonist, prevents the early cerebral vasospasm following subarachnoid hemorrhage after intracisternal but not intravenous injection. Life Science 1993; 52(9): 825-834.
8. Feigin VL, Rinkel GJE, Algra A et al. Calcium antagonists in patients with aneurysmal subarachnoid hemorrhage. Neurology 1998; 50(4): 876-882.
9. Mazurov AV, Menshikov MY, Leytin VL et al. Decrease of platelet aggregation and spreading via inhibition of the cAMP phosphodiesterase by trapidil. FEBS 1984; Lett. 172: 167-171.
10. Okumura R. Enhanced inhibition of platelet function by combination of antiplatelet agents in small doses. Acta. Med. Hyogo 1990; 15: 129-139.
11. Suzuki S, Sobota E, Iwabuchi T. Prevention of cerebral ischemic symptoms in cerebral vasospasm with trapidil, an antagonist and selective synthesis inhibitor of thromboxane A2. Neurosurgery 1981; 9: 679-685.
12. Suzuki Y, Yamaguchi K, Shimida S et al. Antithrombotic activity and the mechanism of action of trapidil. Prostoglandins Leukotrienes Med 1982; 9: 685-695.
13. Ohnishi H, Yamaguchi K. Shimida S et al. A new approach to the treatment of arteriosclerosis and trapidil an antagonist to platelet-derived growth factor. Life Sci 1981; 28: 1641-1646.
14. Ohnishi H, Kosuzume H, Hayashi Y. Effects of trapidil on thromboxane A2-induced aggregation of platelets, ischemic changes in heart and biosynthesis of thromboxane A2. Prostoglandins Med 1981; 6: 269-281.
15. Ohnishi H, Kosuzume H, Yamaguchi K et al. Experimental studies of trapidil on thromboxane A2 (T × A2)-induced aggregation of platelets, ischemic changes in heart and synthesis of T × A2. J Jpn Atheroscler Soc 1979; 7: 407-415.
16. Ott Lyman. Experiments with repeated measures, in (ed): An introduction to statistical methods and data analysis. Chapter 17. PWS - KENT publishing company. Boston. 3rd edition, 1988, pp 794-801.
17. Kassel NF, Peerless SJ, Durward QJ et al. Treatment of ischemic deficits from vasospasm with intravascular volume expansion and induced arterial hypertension. Neurosurgery 1982; 11(3): 337-343.
18. Yano K, Kuroda T, Tanabe Y et al. Preventive therapy against delayed cerebral ischemia after aneurismal subarachnoid hemorrhage: Trials of thromboxane A2 synthetase inhibitor and hyperdynamic therapy. Acta Neurochir (Wien) 1993; 125: 15-19.
19. Polin RS, Hansen CA, German P et al. Intra-arterially administered papaverine treatment of symptomatic cerebral vasospasm. Neurosurgery 1997: 42: 1256-1267.
20. Shiokawa K, Kasuya H, Miyajima M et al. Prophylactic effect of papaverine prolonged-release pellets on cerebral vasospasm in dogs. Neurosurgery 1998; 42: 109-116.
21. Haley EC Jr, Kassel NF, Torner JC. A randomized controlled trial of high dose intravenous nicardipine in aneurysmal subarachnoid hemorrhage: a report of the cooperative aneurysm study. J Neurosurgery 1993; 78(4): 537-547.
22. Han DH, Lee S. Effect of nimodipine treatment on outcome in surgical cases of aneurysmal SAH. J Neurosurg 1993; 78: 346A.
23. Neil-Dwyer G. Mee E. Dorrance D. Lowe D. Early intervention with nimodipine in subarachnoid hemorrhage. Eur Heart J 1987; 8: 41-47.
24. Ohman J, Heiskanen O. Effect of nimodipine on the outcome of patients after aneurysmal subarachnoid hemorrhage and surgery. J Neurosurg 1988; 69: 683-686.
25. Philippon J, Grob R, Dagreou F et al. Prevention of vasospasm in subarachnoid hemorrhage. A controlled study with nimodipine. Acta Neurochir 1986: 82: 110-114.
26. Pickard JD, Murray GD, Ilingworth R et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid hemorrhage: British aneurysmal nimodipine trial. BMJ 1989; 298: 636-642.
27. Egemen N. Baskaya MK, Türker RK et al. Protection by iloprost (stable analogue of prostacyclin) of endothelial damage due to chronic vasospasm in dogs: an electron microscope study. Neurological Research 1995; 17(4): 301-306.
28. Egemen N, Birler K, Avman N, Türker RK. Experimental cerebral vasospasm: Resolution by iloprost. Acta Neurochir 1988; 95: 131-135.
29. Egemen N, Sanlidilek U, Zorlutuna A et al. Transclival approach to rabbit basilar artery for experimental induction of chronic vasospasm. Acta Neurochir (Wien) 1992; 115: 123-126.
30. Egemen N, Türker RK, Sanlidilek U et al. The effect of iloprost on chronic cerebral vasospasm. Gen Pharmac 1993; 24(2): 403-409.
31. Ergün H, Bagdatoglu C, Ugur HC, Attar A, Temiz C, Egemen N, Tulunay FC. The effect of metamizol on experimental cerebral vasospasm model in rabbits Neurological Research 2000 Dec; 22(8): 815-818.
32. Alabadi JA, Torregrosa G, Miranda FJ et al. Impairment of the modulatory role of nitric oxide on the endothelin-1-elicited contraction of cerebral arteries: a pathogenetic factor in cerebral vasospasm after subarachnoid hemorrhage. Neurosurgery 1997; 41(1): 245-252.
33. Egemen N, Türker RK, Sanlidilek U et al. The effect of sodium nitroprussid on severe chronic vasospasm. Neurological Research 1993; 15: 310-315.
34. Pluta RM, Boock RJ, Afshar JK et al. Source and cause of endothelin-1 release into cerebrospinal fluid after subarachnoid hemorrhage. J Neurosurg 1997; 87: 287-293.
35. Pluta RM, Oldfield EH, Boock RJ. Reversal and prevention of cerebral vasospasm by intracarotid infusions of nitric oxide donors in a primate model of subarachnoid hemorrhage. J Neurosurg 1997; 87: 746-751.
36. Zuccarello M, Lewis Al, Rapoport RM et al. Endothelin ETA and ETB receptors in subarachnoid hemorraghe-induced cerebral vasospasm. Eur J Pharmacol 1994; 259: R1-R2.
37. Zuccarello M, Soattin GB, Lewis AI et al. Prevention of subarachnoid hemorrhage-induced cerebral vasospasm by oral administration of endothelin receptor antagonists. J Neurosurg 1996: 84: 503-507.
38. Kwan AL, Bavbek M, Jeng AY et al. Prevention and reversal of cerebral vasospasm by an endothelin-converting enzyme inhibitor, CGS 26303, in an experimental model of subarachnoid hemorrhage. J Neurosurgery 1997; 87(2): 281-286.
39. Kwan AL, Lin CL, Yanamoto H et al. Systemic administration of the potassium channel activator cromakalim attenuates cerebral vasospasm after experimental subarachnoid hemorrhage. Neurosurgery 1998; 42(2): 347-350.
40. Arthur AS, Fergus AH, Lanzino G et al. Systemic administration of iron chelator deferipone attenuates subarachnoid hemorrhage-induced cerebral vasospasm in the rabbit. Neurosurgery 1997; 41(6): 1385-1391.
41. Horky LL, Pluta RM, Boock RJ et al. Role of iron chelator 2,2′-dipyridyl in preventing delayed vasospasm in a primate model of subarachnoid hemorrhage. J Neurosurg 1998; 88: 298-303.
42. Onoue H, Katusic ZS. The effect of subarachnoid hemorrhage on mechanisms of vasodilatation mediated by cyclic adenosine monophosphate. J Neurosurg 1998; 89: 111-117.
43. Chyatte D, Fode NC. Nichols DA et al. Preliminary report: effects of high dose metylprednisolone on delayed cerebral ischemia in patients at high risk for Vasospasm after aneurismal subarachnoid hemorrhage. Neurosurgery 1987; 21(2): 157-160.
44. Nomura H, Hirashima Y, Endo S, Takaku A. Anticardiolipin antibody aggravates cerebral vasospasm after subarachnoid hemorrhage in rabbits. Stroke 1998; 29: 1014-1019.
45. Toyoda T, Kwan AL, Bavbek M et al. Enhanced endogenous antioxidant activity and inhibition of cerebral vasospasm in rabbits by pre-treatment with a non-toxic endotoxin analog, monophosphoryl lipid A. J Neurosurgery 1998; 88: 1082-1087.
46. Tokiyoshi K, Takanori O, Nii Y. Efficacy and toxicity of thromboxane synthetesa inhibitor for cerebral vasospasm after subarachnoid hemorrhage. Surg Neurol 1991; 36: 112-128.
47. Petruk KC, West M, Mohr G et al. Nimodipine treatment in poor-grade aneurysm patients. J Neurosurg 1988; 68: 505-517.
48. Nagakawa Y, Akedo Y, Orimo H. Yano H. Effect of combination of antiplatelet agents in man: Combination of aspirin, trapidil, ticlopidine and dipyridamole. Thrombosis research 1990; 60: 469-475.
49. Okumura R, Hatake K, Wakabayashi I et al. Vasorelaxant effect of trapidil on human basilar artery. J Pharm Pharmacol 1992; 44: 425-428.